Literature DB >> 21727988

Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR α/γ activity in microvascular endothelial cells.

Rosalinda Madonna1, Sara Salerni, Deborah Schiavone, Jan F Glatz, Yong-Jian Geng, Raffaele De Caterina.   

Abstract

Microvascular dysfunction occurs in insulin resistance and/or hyperinsulinaemia. Enhanced uptake of free fatty acids (FFA) and oxidised low-density lipoproteins (oxLDL) may lead to oxidative stress and microvascular dysfunction interacting with CD36, a PPARα/γ-regulated scavenger receptor and long-chain FFA transporter. We investigated CD36 expression and CD36-mediated oxLDL uptake before and after insulin treatment in human dermal microvascular endothelial cells (HMVECs), ± different types of fatty acids (FA), including palmitic, oleic, linoleic, arachidonic, eicosapentaenoic (EPA), and docosahexaenoic (DHA) acids. Insulin (10(-8) and 10(-7) M) time-dependently increased DiI-oxLDL uptake and CD36 surface expression (by 30 ± 13%, p<0.05 vs. untreated control after 24 hours incubation), as assessed by ELISA and flow cytometry, an effect that was potentiated by the PI3-kinase inhibitor wortmannin and reverted by the ERK1/2 inhibitor PD98059 and the PPARα/γ antagonist GW9662. A ≥ 24 hour exposure to 50 μM DHA or EPA, but not other FA, blunted both the constitutive (by 23 ± 3% and 29 ± 2%, respectively, p<0.05 for both) and insulin-induced CD36 expressions (by 45 ± 27 % and 12 ± 3 %, respectively, p<0.05 for both), along with insulin-induced uptake of DiI-oxLDL and the downregulation of phosphorylated endothelial nitric oxide synthase (P-eNOS). At gel shift assays, DHA reverted insulin-induced basal and oxLDL-stimulated transactivation of PPRE and DNA binding of PPARα/γ and NF-κB. In conclusion, omega-3 fatty acids blunt the increased CD36 expression and activity promoted by high concentrations of insulin. Such mechanisms may be the basis for the use of omega-3 fatty acids in diabetic microvasculopathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21727988     DOI: 10.1160/TH10-09-0574

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Co-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts.

Authors:  Rosalinda Madonna; Yong-Jian Geng; Roberto Bolli; Gregg Rokosh; Peter Ferdinandy; Cam Patterson; Raffaele De Caterina
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

2.  Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction.

Authors:  Yang Hu; Ying Chen; Lexi Ding; Xuemin He; Yusuke Takahashi; Yang Gao; Wei Shen; Rui Cheng; Qian Chen; Xiaoping Qi; Michael E Boulton; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-03       Impact factor: 11.205

3.  CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding.

Authors:  Anthony G Jay; Alexander N Chen; Miguel A Paz; Justin P Hung; James A Hamilton
Journal:  J Biol Chem       Date:  2015-01-01       Impact factor: 5.157

4.  n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Brian T Steffen; Lyn M Steffen; Shuang Liang; Russell Tracy; Nancy Swords Jenny; Michael Y Tsai
Journal:  Br J Nutr       Date:  2013-04-03       Impact factor: 3.718

5.  Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.

Authors:  Takuma Higurashi; Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Hiroshi Iida; Takashi Uchiyama; Akiko Ezuka; Shiori Uchiyama; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Shin Maeda; Satoshi Morita; Yutaka Natsumeda; Hajime Nagase; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

6.  The effect of low-dose marine n-3 fatty acids on plasma levels of sCD36 in overweight subjects: a randomized, double-blind, placebo-controlled trial.

Authors:  Stine Krogh Venø; Michael René Skjelbo Nielsen; Søren Lundbye-Christensen; Erik Berg Schmidt; Aase Handberg
Journal:  Mar Drugs       Date:  2013-08-30       Impact factor: 5.118

Review 7.  Effect of Prostanoids on Human Platelet Function: An Overview.

Authors:  Steffen Braune; Jan-Heiner Küpper; Friedrich Jung
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 8.  The role of CD36 in cardiovascular disease.

Authors:  Hongyang Shu; Yizhong Peng; Weijian Hang; Jiali Nie; Ning Zhou; Dao Wen Wang
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.